Here's this week's coronavirus-related news.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), has infected an estimated 26,123,176 individuals worldwide, and approximately 6.1 million Americans. The latest COVID-19 related news includes AstraZeneca’s investigational vaccine expanding into a phase 3 clinical trial and a survey by NCPA gauging pharmacy plans for administering a COVID-19 vaccine.
Here’s a roundup of the latest coronavirus-related news:
AstraZeneca’s investigational COVID-19 vaccine candidate, AZD1222, has expanded into a phase 3 clinical trial, according to a press release.
The US trial, called D8110C00001, is funded by the Biomedical Advanced Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID). The NIAID-supported COVID-19 Prevention Network will participate in the trial.
A new survey conducted by NCPA suggests that most pharmacies plan to offer a COVID-19 immunization service when a vaccine becomes available.
Eighty-six percent of respondents said they plan to offer the COVID-19 vaccines in their pharmacies when they hit the marketplace, according to the survey of nearly 800 community pharmacy owners/managers.
Officials with the FDA have issued Emergency Use Authorization (EUA) for Abbott’s BinaxNOW COVID-19 Ag Card rapid test for the detection of COVID-19, according to a press release.
BinaxNOW delivers results in 15 minutes and will be sold for $5, Abbott said. The test, which is approximately the size of the credit card, is highly portable and easy to use, with no equipment required.